US › Healthcare

PDS Biotechnology Corp (PDSB)

US · Healthcare · Biotechnology

$0.72+0.78%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-7.3M
Profit YoY
+13.4%
EPS
$-0.13
EPS estimate
$-0.14

EPS came in at -0.13 against a street estimate of -0.14 — a beat of 7.1%.

Key statistics

Market cap
$38.4M
Forward P/E
0.0
P/B
9.91
Book value
$0.07
EPS (TTM)
$-0.66
52-week high
$1.55
52-week low
$0.51
50-day MA
$0.91
200-day MA
$0.89
Beta
1.58

Analyst view

Analysts rate PDS Biotechnology Corp a strong buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $7.50.

Shareholding

Insiders
1.51%
Institutions
9.13%

Largest institutional holders

FundStake
Vanguard Capital Management, LLC2.92%
Geode Capital Management, LLC1.18%
BlackRock Inc0.99%
Vanguard Fiduciary Trust Co0.55%
Blair William & Co0.54%
Renaissance Technologies Corp0.39%
Integrys Wealth Advisors LLC0.34%
Armistice Capital, LLC0.31%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for PDS Biotechnology Corp — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.